colleagues suggested that severe viral infections during the first trimester of pregnancy increased autism risk by three times. Later studies of autistic patients have also suggested immune dysfunction as a potential contributing factor. Several proinflammatory cytokines, such as interleukin (IL)-6 and IL-17a, were found to be associated with ASD. Although the specific cellular targets and pathways in the brain are unclear, it is thought that IL-17a signalling during pregnancy might contribute to developmental defects in part of the somatosensory cortex called the S1DZ. In December, 2019, Choi and Huh's teams from MIT and Harvard Medical School (Boston, MA, USA) published an article in Nature that further underscores the role of the immune system in ASD.
Using a preclinical model of ASD in which mice display abnormal social interactions, the authors exposed the mice to lipopolysaccharide (LPS) to induce fever and an immune response. In response to LPS exposure, these mice released IL-17a and-surprisingly-displayed a temporary improvement in social behaviour. Further experiments revealed that IL-17a could bind to receptors in the S1DZ region and inhibit neural activity, thus substantially improving social interactions. IL-17a signalling in the SIDZ region might therefore have a dual effect, depending on the timing and context of IL17a exposure. Another potentially intriguing implication of this article is that the findings could help to explain the connection between fever and symptomatic resolution in ASD. Bal and colleagues from University of California (San Francisco, CA, USA) reported that the behavioural symptoms of 362 (17%) of 2152 children were attenuated during fever (Autism Research, 2018) . Although the IL-17aÀSIDZ signalling pathways are yet to be confirmed in humans, IL-17a might be a molecular clue to the fever phenomenon. As the gut microbiome is known to play a role in IL-17 regulation, future studies will be aimed at exploring whether modulation of gut bacteria could have a similar beneficial effect.
Several genetic animal models have been developed to help advance the mechanistic understanding of ASD and direct genebased therapies for it. These animal models are usually based on one or more known genetic variants of autism. Rodents have been the top choice for a long time, and although they provide much information about the molecular basis of disease, there are also disadvantages in using them to study neurodevelopmental disorders. In particular, mice do not have a highly developed prefrontal cortex-a unique feature of many primates, responsible for decision-making, maintaining concentration, and interpreting social cues. In a 2016 article in Nature, Zilong Qiu's team from Institute of Neuroscience, Chinese Academy of Sciences (Shanghai, China) published the first monkey model for Rett syndrome by overexpressing methyl-CpG binding protein 2, encoded by a gene that is associated with both Rett syndrome and ASD. In 2019, another study published in Nature by Zhou et al (South China Agricultural University, Guangzhou, China and Broad Institute Cambridge, MA, USA) reported the generation of a SHANK3-mutant macaque model for ASD research. These nonhuman primate models might be better suited than mouse models for studying the social aspects of human ASD.
Despite some encouraging growth in the field, we are still far from fully understanding the mechanistic and functional basis of ASD. The development of advanced techniques and improved preclinical models with translational insights will greatly help to move this field forward. EBioMedicine will continue to welcome cutting-edge autism studies that not only offer novel mechanistic insights but also contribute to the development of successful therapies. Contents lists available at ScienceDirect EBioMedicine journal homepage: www.elsevier.com/locate/ebiom
